Raymond James analyst John Ransom upgraded GoodRx to Strong Buy from Outperform with an unchanged price target of $10.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
Questions or Comments about the article? Write to editor@tipranks.com